МОДУЛЯЦІЯ МЕЛОКСИКАМ-ІНДУКОВАНИХ ЗМІН СЕКРЕТОРНОЇ ТА МОТОРНОЇ АКТИВНОСТІ ШЛУНКА ШЛЯХОМ ЗАСТОСУВАННЯ КРІОЕКСТРАКТУ ПЛАЦЕНТИ

Abstract

Introduction. Current approaches to reducing the ulcerogenicity of nonsteroidal anti-inflammatory drugs are aimed primarily at eliminating the damaging effect on the gastric mucosa, and according to the literature, the use of proton pump inhibitors can even worsen the course of enteropathy. Objectives. To characterize the influence of cryopreserved placenta extract on the state of secretory and motor-evacuation activity of the stomach under the conditions of experimental meloxicam-induced gastropathy and enteropathy. Methods. Serial randomized placebo-controlled studies were performed on nonlinear rats and mice using a model of small intestine-induced gastrointestinal lesions. Gastric secretion in rats, gastric evacuation function and intestinal motor function in mice were studied with the help of standard methods. Results. The administration of meloxicam leads to a statistically significant increase (p <0.05) in the volume of gastric secretion by 31.6±7.3%, an increase in total acidity (p=0.002) by 7.7 [7.7; 16.6]% and a statistically significant increase (p<0.05) in peristaltic activity by 18.9% relative to intact animals. The administration of cryopreserved placenta extract led to a statistically significant (p=0.002) decrease in the ratio of free and total acidity by 2.3 times, with a statistically significant decrease (p<0.05) by 14.5% in peristaltic activity relative to intact animals. The combined threaded administration of meloxicam and cryopreserved placenta extract was accompanied by a decrease in the ratio of free and total acidity by 43.0±3.0%. Conclusion. The combined application of placental cryoextract and meloxicam eliminates meloxicam-induced hypersecretion of gastric juice and gastric hypermobility. The cryoextract has also proved to reduce the aggressiveness of gastric juice by reducing its free and increasing combined acidity.